Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.

BMC cancer - 16 Apr 2020

Qin Kang, Hou Helei, Liang Yu, Zhang Xiaochun

Abstract excerpt

BACKGROUND: The prognostic significance of TP53 concurrent mutations in patients with epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)- mutated advanced non-small-cell lung cancer (NSCLC) who received EGFR-tyrosine kinase inhibitors (TKIs) or ALK-TKIs based targeted therapy remains controversial. Therefore, the present meta-analysis was performed to investigate the association between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 32299384
DOI: 10.1186/s12885-020-06805-5
PMCID: PMC7164297

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.PMID 32299384Read ↗

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysisSemantic proximity Read ↗

Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.Semantic proximity Read ↗

Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.Semantic proximity Read ↗

TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer TherapySemantic proximity Read ↗

[Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

The impact of TP53 co-mutation on the clinical outcomes of advanced non-small cell lung cancer patients with EGFR sensitizing mutation: An updated systematic review and meta-analysis of prospective clinical trials and a single-center retrospective cohort studySemantic proximity Read ↗

Effect of EGFR-TP53 co-mutation on the efficacy of EGFR-TKIs in patients with advanced NSCLC and therapeutic strategies: A retrospective study.Semantic proximity Read ↗

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.Semantic proximity Read ↗

The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.Semantic proximity Read ↗

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLCSemantic proximity Read ↗

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.